Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Analyst Outlook | Analyst price targets range from $250 to $400, reflecting varied perspectives on Humana's ability to navigate current challenges and achieve long-term growth |
Strategic Pivot | Explore Humana's multi-year plan leveraging AI and efficiency initiatives to drive clinical excellence and improve margins in response to industry pressures |
Financial Resilience | Despite setbacks, Humana maintains a strong market position with $117.8 billion in annual revenue and a GOOD financial health score |
Medicare Ratings Plunge | Humana faces a critical challenge as its Medicare Advantage star ratings dramatically decline, potentially impacting $1 billion in bonus payments by 2026 |
Metrics to compare | HUM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHUMPeersSector | |
---|---|---|---|---|
P/E Ratio | 26.4x | −32.1x | −0.5x | |
PEG Ratio | −0.53 | −1.08 | 0.00 | |
Price / Book | 1.9x | 19.4x | 2.6x | |
Price / LTM Sales | 0.3x | 1.3x | 2.9x | |
Upside (Analyst Target) | 13.5% | 14.1% | 57.1% | |
Fair Value Upside | Unlock | −7.1% | 9.0% | Unlock |